Steven Landau

Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH.

Oakwood Medical Investors (Oakwood Medical Investors) is a venture capital firm founded in 1997 by Raul Perez. The firm is headquartered in Louis, Missouri.

The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA.

Case Western Reserve University provides educational services. It offers a variety of undergraduate degree courses and graduate and professional options such as arts and sciences, dentistry, engineering, law, management, medicine, nursing, social work, and more. The firm also offers dual-degree programs. The company was founded in 1826 and is headquartered in Cleveland, OH.

Summa Health System, Inc. provides integrated and coordinated care services. It offers medical, specialized, support, and testing services. The company was founded in 1989 and is headquartered in Akron, OH.

Juventas Therapeutics, Inc. provides regenerative therapies for cardiovascular disease. It is a clinical-stage biotechnology company developing a pipeline of factor-based regenerative therapies to treat life-threatening diseases. The company's product has been shown to protect and repair tissue following ischemic injury by recruiting the body's own stem cells to the damaged tissue. The company was founded by Rahul A. Aras and Marc S. Penn in 2007 and is headquartered in Cleveland, OH.

PrognostiX, Inc. discovers and develops biomarker technologies. The firm also offers cardiovascular and inflammatory biomarkers. The company was founded in 2004 and is headquartered in Cleveland, OH.

N-of-One, Inc. engages in the provision of clinical evidence to translate molecular test results into therapeutic options. It offers clinical interpretation, precision insights and clinical trial match solutions. It serves to commercial laboratories, hospital laboratories and medicine programs. The company was founded by Jennifer Levin Carter in 2008 and is headquartered in Lexington, MA.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Corvium, Inc. engages in the development of fist synthetic biology-based bacterial monitoring platform. Its product include Control-Pro, an EMP automation software that converts data into action. The company was founded by Bob Langer, Timothy Lu, Michael Koeris, Brett Chevalier, Micah Rosenbloom, Tanguy Chau, and James J. Collins in March 2009 and is headquartered in Woburnc, MA.

Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA.

Eligo Bioscience SA operates a micobiome engineering laboratory. The company uses synthetic biology and CRISPR and CAS technology to develop highly precise antimicrobials. The firm?s sequence-specific antimicrobials can therefore discriminate between close bacterial strains and selectively eradicate harmful bacteria from the microbiome while sparing the beneficial ones. The company was founded by Timothy Lu, Luciano Marraffini, David Bikard and Xavier Duportet in May 2014 and is headquartered in Paris, France.

Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA.

Tango Therapeutics, Inc. develops transformational new drugs for cancer patients. The company was founded by Alan Ashworth, Jos? Baselga, Levi Garraway, Timothy K. Lu, Antoni Ribas and William G. Kaelin, Jr. in 2017 and is headquartered in Cambridge, MA.

BiomX Ltd. engages in the development of customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease and colorectalcancer, as well as bacteria that affect the appearance of the skin. The company was founded by Eran Elinav, Timothy K. Lu, and Rotem Sorek on March 3, 2015 and is headquartered in Ness Ziona, Israel.

Goodman Capital Ltd (Goodman Capital) is an independent venture capital firm founded in 2013 by Jeffrey Lu and Daphne Teo. The firm is headquartered in Singapore.

Engine Biosciences Pte Ltd. develops novel combinations of genes and drugs for therapeutic and industrial purposes. The company was founded by Timothy Lu and Jeffrey Lu and is headquartered in Singapore.

Rootpath Genomics, Inc. engages in the provision of biotechnology services. It develops personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. The company was founded by Xi Chen, Le Cong, Yinqing Li, Cheryl Cui, and Ely Porter in 2017 and is headquartered in Cambridge, MA.

Keystone Bio, Inc. engages in operation PharmaBiome biotech company. It develops pathogen of chronic inflammation that is shown to initiate and advance Atherosclerosis, heart disease, and Alzheimer's disease. The company is headquartered in St. Louis, MO.

Alexis Bio LLC operates as a clinical-stage biotechnology company. It develops a platform focused on immunogenomic reprogramming of live foreign cells from other species for the purpose of transplanting tissues and organs into human patients. The company was founded by Paul Holzer and Jon Adkins in 2019 and is headquartered in Enfield, NH.

Provectus Algae Pty Ltd. operates as a biotech company specialising in the optimisation of Algae to produce high-value compounds for a broad range of industries and applications. It offers natural and biosynthetic production services in antibiotics, vaccines, enzymes, cosmetics, hormones, terpenes, cannabinoids products.. The company was founded by Nusqe Spanton in 2018 and is headquartered in Noosaville, Australia.

Navigation Sciences, Inc. is a private company that specializes in developing the NaviSci™ system, which provides real-time margin measurement for precision cancer surgery. The company is based in Brookline, MA. The system is designed to address the growing need to locate and remove lung and other soft tissue cancers. The company was founded in 2017 by Jayender Jagadeesan, Alan D. Lucas, and Raphael Bueno. Alan D. Lucas has been the CEO since 2017.

Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015.

Metis Minds, Inc. is a company that offers a digital curriculum called Skylar's Run, which is a video game designed to enhance children's cognitive abilities, including attention, impulse control, and self-regulation. The company is based in Orlando, FL. The game measures and adapts to the child's attention levels, offering a personalized level of challenge. The company was founded by Steven R. Gullans and Barry K. Herman, and Steven R. Gullans has been the CEO since incorporation.